Search Results 271-280 of 17424 for alopecia

  1. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies - Mayo Clinic

    03) except for subjects with alopecia; subjects receiving luteinizing hormone-releasing hormone agonists may be considered for enrollment after discussion with ...

  2. Study of Oral LOXO-338 in Patients With Advanced Blood Cancers - Mayo Clinic

    equal to (≤) 1 or pretreatment baseline, with the exception of alopecia. - Men with partners of childbearing potential or women of childbearing potential ...

  3. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma - Mayo Clinic

    ... alopecia or peripheral neuropathy * Received a cumulative dose of corticosteroids equivalent to \>=70 mg of prednisone within the 7 days (Cohort A, B, C, F) ...

  4. A Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma - Mayo Clinic

    or greater at the time of starting study treatment except for alopecia. - History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen

  5. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Birthmarks, Vulvar skin disorder, Rosacea, Pigmentation disorder, Telogen ...

  6. Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia - Mayo Clinic

    ... alopecia. Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia. Unwilling or unable to participate in all required study evaluations and ...

  7. Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome - Mayo Clinic

    ... alopecia and neuropathy - Patients who are receiving any other investigational agents - History of allergic reactions attributed to compounds of similar ...

  8. Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma - Mayo Clinic

    ... alopecia and/or endocrinopathies related to prior immunotherapy which are controlled with hormone replacement - ELIGIBILITY CRITERIA (STEP 1): Patients must ...

  9. Publications - Afsaneh Alavi, M.D. - Mayo Clinic

    Scarring hidradenitis suppurativa with phrynoderma-like eruption, alopecia, and elevated interleukin 18. JAAD Case Rep. 2025 Jan; 55:116-120 Epub 2024 Nov ...

  10. Publications - Olayemi Sokumbi, M.D. - Mayo Clinic

    Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid. J Drugs Dermatol. 2022 Aug 1; 21 (8):894-895. View PubMed; Pincelli T, Keeling J ...